Pills on green background

Main achievements of Therapeutics research projects and networks

A report on the outputs, outcome and impact generated by the projects funded in the various JPIAMR transnational research project and network calls under the Therapeutics priority topic has been published.

This report has been prepared using information provided by the coordinators of the research projects and networks in the mid-term and the final term progress reports. The aim is to disseminate information about the outputs and the outcomes of the funded projects and networks to highlight the promising results of the funded research. Some highlights from the report on the main achievements of the Therapeutics research projects and networks and the impact generated are:

  • The JPIAMR discovery pipeline resulting from the funded research projects has a high level of diversity including direct acting molecules, potentiators or enablers, anti-virulence agents, repurposed agents, phage and nanobiotics.
  • Six new candidates/leads have been identified and five patents have been filed.
  • In addition to the peer-reviewed scientific articles in highly-recognised journals, the research projects and networks have also published white papers, roadmaps and position papers that can contribute to evidence-based policymaking.

Download the report: JPIAMR therapeutics discovery pipeline: Outputs, outcomes and impact of the funded projects and networks in the Therapeutics priority topic of the JPIAMR-SRIA (pdf 0,8 MB)

Social sciences as a cross-cutting theme in JPIAMR research priorities

The development of resistance to antibiotics is a biological process, but the context that determines emergence and impact of resistance is underpinned by social aspects. Therefore, it is necessary to identify, understand and evaluate these social aspects to enable the prevention and control of AMR.

Using the One Health approach means it is vital to include social processes across human and animal health care, in the food production chain and in environmental protection. Questions to ask are, for example: How do farmers, vets, and regulatory systems manage livestock production? How do regulatory and fiscal frameworks incentivise or deter antimicrobial development, production, availability, and use? How do the public and healthcare professionals understand, value, and use antimicrobials?

There is a need for clearer descriptions of how different social scientific fields – economics, political science, ethics, sociology, anthropology, and law – could deepen the understanding of the AMR issue, and also the value from particular methods such as interviews or ethnography. Once the definition, scale, and scope are understood, we can begin to fully understand the potential contribution of perspectives based on the social sciences.

To start introducing social sciences as a cross-cutting theme in the JPIAMR Strategic Research and Innovation Agenda (SRIA) it is necessary to develop a list of key areas to focus on. It will also be necessary to develop quality assessment criteria that are sufficiently broad to capture the range of quantitative and qualitative methods used by social sciences but specific enough to enable a systematic critique. This exercise will also contribute to the development of the candidate Horizon Europe co-fund OH AMR Partnership.

This initiative is led by professor Katherine Payne, University of Manchester, United Kingdom. An expert group has been appointed, consisting of:

  • Alex Broom, University of Sydney, Australia
  • Anja Schreijer, Erasmus University, The Netherlands
  • Claire Harpet, Université Jean Moulin Lyon 3, France
  • Ian Donald, University of Liverpool, United Kingdom
  • Jon Pierre, University of Gothenburg, Sweden
  • Jonathan Rushton, University of Liverpool, United Kingdom
  • Richard Smith, University of Exeter, United Kingdom
  • Clare Chandler, London School of Hygiene & Tropical Medicine, United Kingdom

The group is currently drafting a working paper that will be sent for wider consultation among experts before being included in the SRIA revision process.

Illustration of Candida auris

Review from the JPIAMR SRIA fungal resistance group published in Nature Reviews Microbiology

JPIAMR is pleased to share the following review that was published in Nature Reviews Microbiology: Tackling the emerging threat of antifungal resistance to human health. The review was written by the expert group on antifungals that led the broadening on the JPIAMR Strategic Research and Innovation Agenda in 2021.

“Our review articulates the neglected aspect of antifungal resistance, and outlines where attention is needed to address this burgeoning problem. In particular, One-Health drivers require specific policy-led attention as it is here that agricultural practice conflicts with public health necessities – we hope that our article will focus attention on these increasingly urgent issues.” – Mat Fisher, Imperial College London, UK

The JPIAMR Strategic Research and Innovation Agenda was broadened in 2021 to include antifungal priorities for research and innovation.

“The article marks an important change in the JPIAMR Strategic Research and Innovation Agenda, which now incorporates antifungal resistance in its research goals. Fungal resistance proposals are eligible for funding in current and future calls, thereby enabling the international scientific community to address increasing challenges regarding the epidemiology, diagnosis and management of antifungal resistance.” – Paul E. Verweij, Radboud University Nijmegen Medical Center, the Netherlands

Scientific Research and Innovation Agenda picture

Strategic Research and Innovation Agenda – global survey

The JPIAMR has launched a round of public consultation on the Strategic Research and Innovation Agenda (SRIA) on Antimicrobial Resistance.  The (SRIA) presents an overview of recent developments and future needs for AMR research. More information and the link to the SRIA can be found here: JPIAMR Strategic Research and Innovation Agenda

The updated SRIA outlines five key priority topics within the AMR field: Therapeutics, Diagnostics, Surveillance Transmission and Evolution, and Prevention and Intervention.

The SRIA is a prime guiding tool for AMR research prioritisation in investments, research activities and planning for JPIAMR member states and other funding initiatives. It is also one of the most thorough guidelines on AMR research, helping researchers, policymakers, media, educators, health workers and the scientific community to work together on solutions to curb AMR on a global scale.

You can contribute to the consultation by completing the following survey: JPIAMR SRIA global survey

The survey will be closed on 15th April 2022 at 12.00 CET.

Call picture

Research call on drug resistance now open

The transnational project call Disrupting drug resistance using innovative design is now open. The call involves 27 funding organisations from 18 countries and the total estimated call budget is about 19 million Euro.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

The call will follow a two-step evaluation procedure and the deadline for pre-proposals is 8 March 2022.

Read more on the Disrupting drug resistance using innovative design call page.

Transmission dynamics 2016 call picture

Main achievements of the AMR Transmission Dynamics call

The outputs, outcomes and the impact generated by the projects supported under the 2016 JPIAMR joint co-funded call “AMR Transmission Dynamics have now been published in a report. The report highlights the effect of supporting excellent science through transnational research collaborations.

Numerous peer-reviewed scientific articles in highly recognised journals have been published by the supported projects on the research findings, and a patent has been filed on a new peptide molecule discovered in one of the projects.

Other impact highlights are:

  • New knowledge generation to address AMR at regional, national and global scale with a One Health approach.
  • Science-based policy and societal impact.
  • Innovative tools and analytical methods and technologies.
  • Interdisciplinary expertise in transnational collaboration.

Download the report (pdf 1 MB): 2016 call on AMR Transmission Dynamics: Research outputs, outcome and impact of the projects

AMR Transmission Dynamics call

The third JPIAMR joint co-funded call “AMR Transmission Dynamics” was launched in 2016. The call was conducted by 21 participating funding organisations from 18 countries and was co-funded by the European Commission (EC) within the JPI-EC-AMR ERA-Net co-fund grant . The call resulted in the awarding of 29.1 million euros (M EUR) including a 6.3 M EUR contribution from the EC to 19 research projects. The 19 project consortia included a total of 118 researchers from 16 countries aiming to bridge the knowledge gap on AMR transmission mechanisms.

The call was one of the first of its kind to address transmission of antibiotic resistance following a One Health approach not only focussing the European and North American countries but also including research activities in the low- and middle-income countries (LMIC).

Flag of Chile

Chile new member of JPIAMR

We are pleased to welcome Chile as a new member of JPIAMR. Chile’s participation in JPIAMR is part of the country’s determination to become an active contributor to the world’s efforts to tackle the global challenge of AMR.

Chile is represented in JPIAMR by MICROB-R on behalf of the Ministry of Health.

Tania Herrera, Coordinator Chile National AMR Plan:

-As an JPIAMR member, we expect to advance collaborative efforts on ambitious, innovative, large scale research projects, introducing meaningful progress in our knowledge base to tackle the global challenge of AMR.

Andrea Moreno Switt, Associate Professor, Pontificia Universidad Católica de Chile:

-In the context of Chile’s newly launched version of its AMR National Plan, JPIAMR membership represents our renewed efforts and conviction that Chilean agenda and capabilities on AMR research are having a substantial upgrade, and that we are in solid shape to undertake collaborative projects benefiting the international AMR research community.

Jan-Ingvar Jönsson, JPIAMR Chair:

On behalf of the JPIAMR Management Board, I am extending a warm welcome to Chile as the 29th member of JPIAMR. It is with great pleasure and excitement that we are including yet another country in Latin America. We are looking forward to create opportunities for researchers in Chile to participate in future calls. The membership will unlock new research collaborations that may contribute to a deeper understanding of AMR and potentially, solutions to one of the key challenges of our time.

Read more on Chile’s national AMR research program and activities.

JPIAMR celebrating 10 years

JPIAMR celebrating 10 years of achievements

It is with great pleasure that we acknowledge that JPIAMR officially celebrates ten years as an international collaborative platform. From its inception in December 2011 until today, JPIAMR has achieved and exceeded its mission to coordinate national funding of antimicrobial resistance (AMR) research, guided by a shared strategic research and innovation agenda. Today 28 countries fund AMR research with a One Health approach, as members of JPIAMR. More than 1 400 researchers in 71 countries have been engaged in research that has been funded by JPIAMR members. In total, 125 million Euros have been allocated to research and networking which has achieved outstanding results and impacts. This highlights the role of JPIAMR as a key initiative helping to understand and curb AMR on a global scale.

JPIAMR is leading the development of the One Health AMR Partnership within the Horizon Europe Framework Programme. We look forward to working together with members to seek and support solutions to curb AMR.

“It is impressive to see what JPIAMR members have made possible during these ten years. The results from funded research are astonishing and important, showing that the JPIAMR model works. JPIAMR is well suited to lead the development of the One Health AMR Partnership. We can only imagine what will be achieved in the ten years to come. I am joining all of the members and the AMR research community in wishing JPIAMR a Happy Birthday!” – Jan-Ingvar Jönsson, JPIAMR Chair

See highlights from JPIAMR’s ten year history in the folder “JPIAMR Ten years of achievements” (pdf 0,5 MB)

Call picture

Pre-announcement: Research call on drug resistance

We are pleased to pre-announce the transnational project call Disrupting drug resistance using innovative design under the umbrella of the JPIAMR. The call will involve 26 funding organisations from 17 countries and the total estimated call budget is about 17 million Euro.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

The call opens on 11 January 2022.

Read more on the Disrupting drug resistance using innovative design call page.